Indolidan
Indolidan (LY195115) is an orally active cardiotonic agent and a selective cyclic nucleotide phosphodiesterase inhibitor. Indolidan has a Ki of 80 nM for sarcoplasmic reticulum phosphodiesterase (SR-PDE). Indolidan exhibits positive inotropic and vasodilator effects. Indolidan can be used in the research of diseases such as congestive heart failure.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 100643-96-7
- Formel: C14H15N3O2
- Molecular Weight:257.29
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Chemical Information
-
CAS. Nr. 100643-96-7
-
Molecular Weight 257.29
-
Formel C14H15N3O2
-
SMILES
CC1(C2=CC(C(CC3)=NNC3=O)=CC=C2NC1=O)C
-
Synonyms
LY195115
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Reinheit & Dokumentation
Verweise
[1]. Hayes JS, et al. Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of action. J Cardiovasc Pharmacol. 1987 Apr;9(4):425-34. [Content Brief]
[2]. Kauffman RF, et al. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol. 1986 Dec;30(6):609-16. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Indolidan Related Classifications
HY-165439 Related Classifications
Powered by Bioz